The year 2017 stands as a definitive milestone in the history of American medicine. It was then that the U.S. Food and Drug Administration approved the first gene therapy ever cleared for use in the United States.
That therapy, known commercially as Kymriah (tisagenlecleucel), emerged directly from the laboratory of Dr. Carl H. June and his team at the University of Pennsylvania. By any measure, the approval marked the moment when a once-theoretical approach to fighting cancer became a practical, commercial reality.
For patients with certain forms of blood cancer, and for investors who had watched the field from a distance, the event signaled a permanent shift in the treatment landscape.
A Decade of Breakthroughs
The road to that regulatory milestone began years earlier. In 2010, June’s team reported the first successful use of a novel treatment method called CAR-T cell therapy in a patient suffering from chronic lymphocytic leukemia.
That single case opened the door to an entirely new class of medicine. CAR-T cell therapy works by genetically modifying a patient’s own T cells so that they can recognize and destroy cancer cells. The approach, which June pioneered, effectively rewires the body’s immune system to attack malignancies that had previously resisted standard treatments.
The 2010 success was the critical proof of concept, and it set the stage for the landmark FDA approval in 2017. That year, Kymriah was authorized for pediatric acute lymphoblastic leukemia, a disease that had long been one of the most difficult to treat in young patients.
The 2017 approval was not just a win for one institution or one researcher. It transformed the entire field of cell therapy, turning an academic promise into a commercial product. For investors, it was the signal that the technology had legs. For patients and their families, it offered a new option where few had existed before.
June’s work did not stop there. His lab had already spent years laying the scientific foundation.
Early on, his team investigated the CD28 molecule, a key control switch for T cells, and that work became the basis for the CAR-T approach. They also tested genetically modified T cells in patients with HIV, demonstrating that the modified cells could persist in the body for years. Those experiments built the knowledge that eventually made the 2010 leukemia case possible.
From Naval Service to the Lab Bench
Carl H. June’s path to becoming a pioneer in immunotherapy began far from the laboratory. Born in 1953, he graduated from the U.S. Naval Academy and later earned his medical degree.
His early research focused on transplantation biology, and he worked with leading figures in that field at the Fred Hutchinson Cancer Center in Seattle. After that, he founded the Immune Cell Biology Program at the Naval Medical Research Center, an institution where he could combine his military service with scientific inquiry.
In 1999, June joined the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he remains a professor. His background in the Navy shaped his approach to research—disciplined, systematic, and oriented toward practical outcomes. June’s contributions have not gone unrecognized.
In 2018, he received both the Lasker Award and the Breakthrough Prize, two of the most prestigious honors in biomedical science. He was also elected to the American Philosophical Society, and the U.S. Navy awarded him the Legion of Merit, its highest scientific honor.
These accolades reflect the depth of his impact on medicine.
The Next Frontier: Solid Tumors and Autoimmune Diseases
Today, June’s research continues. The focus has shifted to next-generation CAR-T cells designed to tackle two of the most stubborn challenges in medicine: solid tumors and autoimmune diseases.
The central question for the field is whether the same technology that rewrote the rules for blood cancers can be adapted to attack solid tumors. The answer is not yet clear, but the track record suggests it is worth watching. The same laboratory that pioneered the first U.S. gene therapy is now pushing into uncharted territory, and the scientific community is watching closely.
As with any medical development, individuals should consult their doctor for medical advice.
